Neoplasm Recurrence, Local
"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Descriptor ID |
D009364
|
MeSH Number(s) |
C04.697.655 C23.550.727.655
|
Concept/Terms |
Neoplasm Recurrence, Local- Neoplasm Recurrence, Local
- Local Neoplasm Recurrences
- Locoregional Neoplasm Recurrence
- Recurrences, Local Neoplasm
- Neoplasm Recurrences, Local
- Recurrence, Local Neoplasm
- Recurrence, Locoregional Neoplasm
- Local Neoplasm Recurrence
- Neoplasm Recurrence, Locoregional
- Locoregional Neoplasm Recurrences
- Neoplasm Recurrences, Locoregional
- Recurrences, Locoregional Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".
This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 8 | 25 | 33 |
1995 | 17 | 26 | 43 |
1996 | 19 | 37 | 56 |
1997 | 13 | 27 | 40 |
1998 | 16 | 40 | 56 |
1999 | 21 | 27 | 48 |
2000 | 20 | 32 | 52 |
2001 | 19 | 41 | 60 |
2002 | 32 | 31 | 63 |
2003 | 55 | 44 | 99 |
2004 | 57 | 49 | 106 |
2005 | 52 | 66 | 118 |
2006 | 60 | 65 | 125 |
2007 | 61 | 69 | 130 |
2008 | 68 | 60 | 128 |
2009 | 46 | 84 | 130 |
2010 | 69 | 82 | 151 |
2011 | 74 | 76 | 150 |
2012 | 87 | 49 | 136 |
2013 | 82 | 93 | 175 |
2014 | 106 | 67 | 173 |
2015 | 110 | 87 | 197 |
2016 | 107 | 48 | 155 |
2017 | 110 | 76 | 186 |
2018 | 108 | 82 | 190 |
2019 | 94 | 80 | 174 |
2020 | 103 | 119 | 222 |
2021 | 66 | 153 | 219 |
2022 | 13 | 154 | 167 |
2023 | 12 | 148 | 160 |
2024 | 0 | 17 | 17 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
ASO Visual Abstract: Local Therapy Improves Survival for Early Recurrence After Resection of Colorectal Liver Metastases. Ann Surg Oncol. 2024 Apr; 31(4):2606.
-
Lost in Translation: Failure of Preclinical Studies to Accurately Predict the Effect of Regional Analgesia on Cancer Recurrence. Anesthesiology. 2024 Mar 01; 140(3):361-374.
-
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024 Apr; 211(4):518-525.
-
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024 Apr; 211(4):526-532.
-
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. J Urol. 2024 Apr; 211(4):509-517.
-
Endoscopic Versus Microscopic Transcanal Resection of Glomus Tympanicum: A Retrospective Comparative Study. Otol Neurotol. 2024 Apr 01; 45(4):426-429.
-
The importance of considering competing risks in recurrence analysis of intracranial meningioma. J Neurooncol. 2024 Feb; 166(3):503-511.
-
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024 Feb 08; 143(6):496-506.
-
ASO Visual Abstract: Racial and Ethnic Disparities in Outcomes after Breast-Conserving Therapy and Endocrine Therapy for DCIS-A Post Hoc Analysis of the NSABP B-35 Randomized, Clinical Trial. Ann Surg Oncol. 2024 02; 31(2):1010-1011.
-
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX. Blood Adv. 2024 01 23; 8(2):388-398.